

Information about proposed for board of directors – annual general meeting 2009

Proposal for re-elections and new elections of members of the board of directors:

Håkan Åström, Chairman

Born 1947. M.Sc. in Business Administration and Economics. Med. Dr. h.c. Sahlgrenska Academy, Gothenburg University 2003. Board member since 2001. Board member of Karolinska Institutet (vice-chairman), Affibody (Chairman), Ferrosan AS (Chairman), Orexo AB (Chairman), Rehnman och Partners, SANOS AS (Chairman), and Topotarget AS (Chairman). Former CEO Kabi Pharmacia and Senior Vice President, Pharmacia Corporation.

Holdings: 50,000 shares, 0 options

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Hans Glemstedt

Born 1962. Graduate and MBA from Stockholm School of Economics. Former Senior Manager at McKinsey during 9 years. 10 years of private equity and venture capital investment experience prior to joining Investor AB as a team member in the Operating Investment group 2006.

Holdings: 0 shares, 0 options

Independent in relation to the company and its management, but dependent in relation to the company's principal shareholders.

Mats-Olof Ljungkvist

Born 1951. B.Sc. in Economics and Business Administration. Board member since 2007. Senior Adviser, Atos Consulting AB. Board member of HL Display AB, SBC Sveriges BostadsrättsCentrum AB, Catella Sponsor AB, Amplion AB, SwedSec AB, Swegro AB, Hermods AB (Chairman), Twentyfourseven AB (Chairman) and Tema Arkitekter AB. Former CFO in Carnegie & Co, CEO in Aragon and CFO in Apoteksbolaget.

Holdings: 2,000 shares, 0 options

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Wenche Rolfsen

Born 1952. Pharm. Dr. Professor Pharmaceutical Faculty, Uppsala University. Board member since 2004. Currently Board member of Aprea (Chairman), Denator (Chairman), Artimplant, Industrifonden and Aker Biomarine AS, Norway. Wenche Rolfsen has held senior management positions at former PharmaciaUpjohn, has

N.B. The English text is an in-house translation

been CEO at Quintiles AB and Vice President Quintiles Europe, Explorative Clinical Research.

Holdings: 20,400 shares, 0 options

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Peter Sellei

Born 1960. M.D. Karolinska Institutet 1987. Former thoracic surgeon at Karolinska Hospital until 1996 and pharma analyst until 2003. Responsible for the Healthcare Sector in the Core Investment Department at Investor AB. Neuronova Board substitute member.

Holdings: 0 shares, 0 options

Independent in relation to the company and its management, but dependent in relation to the company's principal shareholders.

Michael Steinmetz

Born 1947. Ph.D. Board member since 2001. Managing Director, Clarus Ventures. General Partner MPM Capitals Funds Bio Ventures I, II and III. Board member of Allozyne (Chairman), CGI Pharmaceuticals, ESBATech, MacroGenics, Oxford Immunotec, TaiGen (Chairman), Virdante (Chairman) and VLST.

Holdings: 0 shares, 0 options

Independent in relation to the company and its management, but dependent in relation to the company's principal shareholders.

Hans Wigzell

Born 1938. MD, Ph. D. Professor Immunology. Board member since 2004. Chairman of Biovitrum Scientific Advisory Board since 2001. Member of the Royal Swedish Academy of Sciences and the Royal Swedish Academy of Engineering Sciences. President of Karolinska Institutet 1995-2003. Member of the Board of the Karolinska Development AB (Chairman) RaySearch AB, Probi AB, Intercell AG and Neodynamics.

Holdings: 60,000 shares, 0 options

Independent in relation to the company and its management and in relation to the company's principal shareholders.